New treatment for depression in adolescents using brain stimulation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of Stanford Accelerated Intermittent Neuromodulation Therapy (SAINT®) in treating major depressive disorder in adolescents aged 14-19 who have not previously received antidepressant treatment. Participants will undergo a series of transcranial magnetic stimulation sessions aimed at reducing depressive symptoms, with their progress monitored through standardized depression rating scales. The study will also gather feedback from both adolescents and their parents regarding the treatment's acceptability as a first-line option for depression. The trial aims to enroll approximately 40 participants and will assess outcomes at baseline and one month post-treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or Female, between the ages of 13 and 20 at the time of screening.
2. Able to read, understand, and provide written, dated assent and/or consent prior to screening. Proficiency in English sufficient to complete questionnaires and follow instructions during aiTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.
3. Diagnosed with Major Depressive Disorder (MDD) with a current Major Depressive Episode (MDE), according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5).
4. No prior major depressive episodes (MDEs) as determined by MINI-KID
5. CDRS-R score of ≥40 at screening (Visit 1).
6. Treatment-naive as determined by the ATHF (no adequate antidepressant trials prior to screening defined as fewer than 12 weeks of antidepressant medication in the past 2 years and fewer than 10 psychotherapy sessions for depression in the past year; willingness to taper medications and stop psychotherapy if recently started and within the window defined above.)
7. TMS naive.
8. Access to ongoing psychiatric care before and after completion of the study.
9. In good general health, as evidenced by medical history.
10. Agreement to adhere to Lifestyle Considerations throughout study duration.

Exclusion Criteria:

1. Pregnancy
2. High-risk for suicide or active suicidal ideation as determined by clinical interview
3. The presence or diagnosis of prominent anxiety disorder, or dysthymia (\>4 on SAPAS; \>16 on GAD-7)
4. Current severe insomnia (must sleep a minimum of 5 hours each night before stimulation)
5. Current mania or psychosis
6. Bipolar Affective Disorder and/or primary psychotic disorders.
7. Autism Spectrum disorder or Intellectual Disability
8. A diagnosis of obsessive-compulsive disorder (OCD)
9. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal.
10. Urine screening test positive for illicit substances.
11. Any history of ECT (greater than 8 sessions) without meeting responder criteria
12. Recent (during the current depressive episode) or concurrent use of a rapid acting antidepressant agent (i.e., ketamine or a course of ECT).
13. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, unexpected seizure/epilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma.
14. Untreated or insufficiently treated endocrine disorder.
15. Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion)
16. Contraindications to MRI (ferromagnetic metal in their body).
17. Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
18. Depth-adjusted aiTBS treatment dose \> 65% maximum stimulator output (MSO)
19. Treatment with another investigational drug or other intervention within the study period.
20. Any other condition deemed by the PI to interfere with the study or increase risk to the participant.

Where it's running

• Dell Medical School at University of Texas at Austin
  Austin, Texas, United States Recruiting

Study contacts

• Principal investigator: Sean J O'Sullivan, M.D., Ph. D. — University of Texas at Austin
• Study coordinator: Daniella Santos
• Email: daniella.santos@austin.utexas.edu
• Phone: 512-495-5566

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sleep-to-Mood in Depression: Home-based tDCS

  This study tests whether home-based tDCS for adults with moderate depression helps sleep improve and whether better sleep is linked to mood improvements.

  Recruiting NYU Langone Health · New York, New York · NCT07572526

• Identifying biomarkers for depression and suicide in adolescents

  This study is trying to find specific markers in the body that can help understand depression and suicidal thoughts in teenagers, while also looking at how standard treatments affect these issues.

  Recruiting at 2 sites University of Alabama at Birmingham · Birmingham, Alabama and 1 other locations · NCT05437588

• Comparing two types of brain stimulation for treatment-resistant depression

  This study is testing if a new type of brain stimulation can help people with treatment-resistant depression just as well as a current method they already use.

  Recruiting at 2 sites University of British Columbia · Vancouver, British Columbia and 1 other locations · NCT04999553

• Remote monitoring for adults with depression using ThIA Suivi

  This study tests whether adding the ThIA Suivi remote monitoring tool to usual psychiatric care helps adults with depression feel more improved after 3 months compared with standard care alone.

  Recruiting at 3 sites Phase 1 ThIA Santé Mentale · Bron and 2 other locations · NCT07878754

• Mindfulness‑augmented brain stimulation for treatment‑resistant depression

  This trial will test whether combining fast brain stimulation (iTBS) with a digital mindfulness program helps people with treatment‑resistant depression reduce symptoms and improve thinking.

  Recruiting Phase 2 University of California, San Diego · San Diego, California · NCT07512284

• Remote Depression Monitoring with Smartphone Data and Alerts

  This study tests whether data from a patient's smartphone can help predict if depressive symptoms will come back after treatment.

  Recruiting at 2 sites Dartmouth-Hitchcock Medical Center · Hanover, New Hampshire and 1 other locations · NCT07174557

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.